FIC oral, once-daily, dual ETA/AT1 antagonist
FDA-approved for proteinuria reduction in primary IgAN
opt. of known ETA/AT1 antagonist
FDA accelerated approval, February 17, 2023
Travere Therapeutics, San Diego, CA
sparsentan
5 mins read
An old BMS program revitalized as a first-in-class drug in a new indication. Despite Travere Therapeutics having a checkered industry history due to ties to Martin Shrkeli, there appears to be potentially differentiating efficacy for sparsentan’s (Filspari) accelerated approval thanks to its novel dual-antagonistic mechanism. It’s also another example of a large pharma program (BMS346567) finding a new life in a different indication. Sparsentan’s approval represents the first non-immunosuppressive therapy for IgA nephropathy (IgAN), a rare kidney disease. A company with a checkered history, but an efficacious drug for rare kidney disease. Travere Therapeutics was originally named Retrophin and founded in 2008 by Martin Shkreli. The company fired the CEO in 2014 after Shkreli raised the price of tiopronin by…
Search By Structure
Molecules of the Month
2023
2022
2021
2020